A Comparison of Adverse Events Among Radiofrequency Ablation, Conventional Transarterial Chemoembolization (TACE) and Drug-Eluting Bead TACE in Treating Hepatocellular Carcinoma Patients

被引:4
|
作者
Cao, Guangshao [1 ]
Liu, Yuyan [1 ]
Li, Lupeng [1 ]
Zhao, Xiaoyang [1 ]
Liu, Ruiqing [1 ]
Liu, Jian [1 ]
Liu, Jianwen [1 ]
Cao, Huicun [1 ]
机构
[1] Henan Univ, Zhengzhou Univ, Henan Prov Peoples Hosp, Peoples Hosp,Dept Intervent, 7 Weiwu Rd, Zhengzhou 450003, Henan, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2021年 / 13卷
关键词
hepatocellular carcinoma; conventional transarterial chemoembolization; drug-eluting bead transarterial chemoembolization; radiofrequency ablation; adverse events; TRIAL;
D O I
10.2147/CMAR.S308097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There has been very limited investigation regarding the comparison of adverse events (AEs) among radiofrequency ablation (RFA), conventional transarterial chemoembolization (cTACE), and drug-eluting bead TACE (DEB-TACE) in treating HCC patients; therefore, the present study aimed to resolve this issue. Methods: Two-hundred and forty-six HCC patients (with a total of 267 procedures [treatment times]) treated with RFA (73 patients with 79 procedures), cTACE (86 patients with 94 procedures), or DEB-TACE (87 patients with 94 procedures) were included. Demographic and clinical data were collected. The information on AEs was also retrieved and analyzed. Results: Total AEs incidence was notably different among the RFA group, cTACE group, and DEB-TACE group and was the highest in cTACE group (86.2%), then in DEB-TACE group (76.6%), and the lowest in RFA group (63.3%). Regarding specific AEs incidence, the incidences of fever, fatigue, and nausea were distinctive among the three groups, while no distinctiveness was found in incidence of other AEs. Furthermore, multivariate logistic regression revealed that cTACE (versus RFA) was independently correlated with increased risk of total AEs, fatigue, and nausea/vomiting; however, the interventional therapies were not independently correlated with the risk of pain, fever or constipation. Other independent predictive factors for total AEs risk were male gender, bronchial asthma, and disease duration. Conclusion: cTACE resulted in the highest AEs incidence compared with RFA and DEBTACE in treating HCC patients.
引用
收藏
页码:5373 / 5382
页数:10
相关论文
共 50 条
  • [31] Drug-Eluting Bead Transarterial Chemoembolization Versus Radiofrequency Ablation as an Initial Treatment of Single Small (≤ 3 cm) Hepatocellular Carcinoma
    Lee, Somin
    Jeong, Yong Yeon
    Lee, Byung Chan
    Shin, Sang Soo
    Heo, Suk Hee
    Kim, Hyoung Ook
    Park, Chan
    Jeong, Won Gi
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (42)
  • [32] Transarterial chemoembolization with drug-eluting beads (DEB TACE) for BCLC-A hepatocellular carcinoma (HCC): a radical option?
    Manini, Matteo A.
    Iavarone, Massimo
    Martinetti, Laura
    Sangiovanni, Angelo
    Grassi, Eleonora
    Crespi, Silvia
    Colombo, Massimo
    Nicolini, Antonio F.
    HEPATOLOGY, 2012, 56 : 476A - 476A
  • [33] Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma
    Jeong Eun Song
    Do Young Kim
    World Journal of Hepatology, 2017, (18) : 808 - 814
  • [34] Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: Efficacy, safety, and prognostic factors
    Zhang, Hao
    Wu, Chunxue
    Chen, Miaoling
    Sun, Yuandong
    Han, Jianjun
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (06) : 1525 - 1532
  • [35] The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma
    Li, Hao
    Liang, Chao
    Kuang, Donglin
    Huang, Guohao
    Zhang, Mengfan
    Chen, Pengfei
    Zheng, Qingzhu
    Xu, Wenze
    Ren, Jianzhuang
    Han, Xinwei
    Duan, Xuhua
    CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [36] Conventional versus drug-eluting bead transarterial chemoembolization:A better option for treatment of unresectable hepatocellular carcinoma
    Murtuza Razi
    Gu Jianping
    He Xu
    Mohammed Jameeluddin Ahmed
    Journal of Interventional Medicine, 2021, 4 (01) : 11 - 14
  • [37] A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials
    Wang, Hongye
    Cao, Cheng
    Wei, Xiyi
    Shen, Kangjie
    Shu, Yimei
    Wan, Xiaojie
    Sun, Jinyu
    Ren, Xiaohan
    Dong, Yuxiang
    Liu, Yihai
    Zhai, Bo
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (02) : 243 - 249
  • [38] Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study
    Wen, Ping
    Chen, Sheng-Duo
    Wang, Jia-Rui
    Zeng, Ying-He
    ONCOLOGY RESEARCH, 2019, 27 (05) : 583 - 592
  • [39] Drug-eluting bead transarterial chemoembolization is efficient and well-tolerated in treating elderly Chinese hepatocellular carcinoma patients
    Zhou, Yiming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (10): : 4867 - 4878
  • [40] Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma
    Prajapati, Hasmukh J.
    Dhanasekaran, Renumathy
    El-Rayes, Bassel F.
    Kauh, John S.
    Maithel, Shishir K.
    Chen, Zhengjia
    Kim, Hyun S.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2013, 24 (03) : 307 - 315